Sepsis is a body’s reaction to infection, it may develop from any type of infection. Increasing prevalence of sepsis is leading to an increasing need for early diagnosis. Hence, the demand for related diagnostic products is also anticipated to increase. In response to the increasing demand and
need, the manufacturers of diagnostic products are also investing in the research and development of new products. This Fact.MR report analyzes the expansion of global sepsis diagnostics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2026.
According to a study by Fact.MR, the sepsis diagnostics market is expected to witness strong growth, registering 7.7% CAGR during the forecast period 2017-2026. The global sepsis diagnostics market is also projected to generate US$ 707.3 million revenue by the end of 2026. Owing to the increase in scope and applications, significant growth is expected in the market. Moreover, early detection has been shown to be crucial for the better outcome of patients suffering from sepsis. Following are the insights on how the global sepsis diagnostics market will perform in the coming years.
Report provides an overview of the global sepsis diagnostics market. This comprises an introduction to the market, along with a standard definition of the product – sepsis diagnostics. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period. The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.
North America expected to emerge as the largest region in the global sepsis diagnostics market throughout the forecast period. By the en
Considering the broad scope of the global sepsis diagnostics market, the report by Fact.MR provides key insights and segmentation analysis and forecast. The global sepsis diagnostics market is segmented into product type, method, pathogen, technology, and region. The segment-wise analysis also provides detailed country-wise forecast by taking into account all the key parameters of the global sepsis diagnostics market. The report’s last section comprises of d of 2026, North America is projected to exceed US$ 200 million revenue. Well-established healthcare infrastructure, the rise in adoption of advanced products is driving the growth of the market in the region. Moreover, septic poisoning is one of the leading causes of death in the U.S.
Assays & Reagents to Emerge as the Top-Selling Product
Among various products in sepsis diagnostics market, assays & reagents are likely to emerge as the top-selling products. Assays & reagents are projected to surpass US$ 300 million revenue by end of the forecast period. Reagents and assays kits are showing lucrative growth due to the introduction of technically advanced tests by key players. Moreover, assays and reagents facilitate early diagnosis of sepsis.
Browse Full Report on Sepsis Diagnostics Market with TOC-
Sepsis is a severe illness triggered by body’s response to an infection. Factors that are resulting in the growth of sepsis diagnostics market are the rise in aging population, increasing incidences of hospital acquired infections and the growth in the development of innovative products and approvals of those products. Major market players are also increasingly investing in the research and development of new treatments, tests and interventions in order to detect, treat and prevent diseases. Depending on the symptoms, various tests are being performed including blood tests, laboratory tests, and imaging scans. Also, a lot of diagnostic tools are under the approval process and clearance by the Food and Drugs Administration (FDA).
The report has also profiled leading companies in the global market for sepsis diagnostics, which will remain active through 2026. These include companies such as Biomérieux SA, Quidel Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Luminex Corporation, Abbott Laboratories, Inc., T2 Biosystems, Inc., Roche Holdings AG (Roche Diagnostics Limited), Danaher Corporation (Beckman Coulter, Inc.), Qiagen NV, Siemens Healthineers, and Abionic SA.